These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 29613856)

  • 1. TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer.
    Gong K; Guo G; Gerber DE; Gao B; Peyton M; Huang C; Minna JD; Hatanpaa KJ; Kernstine K; Cai L; Xie Y; Zhu H; Fattah FJ; Zhang S; Takahashi M; Mukherjee B; Burma S; Dowell J; Dao K; Papadimitrakopoulou VA; Olivas V; Bivona TG; Zhao D; Habib AA
    J Clin Invest; 2018 Jun; 128(6):2500-2518. PubMed ID: 29613856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
    Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
    Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
    Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
    Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
    Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
    Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
    Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-150 promotes cellular metastasis in non-small cell lung cancer by targeting FOXO4.
    Li H; Ouyang R; Wang Z; Zhou W; Chen H; Jiang Y; Zhang Y; Li H; Liao M; Wang W; Ye M; Ding Z; Feng X; Liu J; Zhang B
    Sci Rep; 2016 Dec; 6():39001. PubMed ID: 27976702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
    Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
    Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3.
    Tang J; Guo F; Du Y; Liu X; Qin Q; Liu X; Yin T; Jiang L; Wang Y
    Int J Oncol; 2015 May; 46(5):2083-95. PubMed ID: 25695284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.
    Blakely CM; Pazarentzos E; Olivas V; Asthana S; Yan JJ; Tan I; Hrustanovic G; Chan E; Lin L; Neel DS; Newton W; Bobb KL; Fouts TR; Meshulam J; Gubens MA; Jablons DM; Johnson JR; Bandyopadhyay S; Krogan NJ; Bivona TG
    Cell Rep; 2015 Apr; 11(1):98-110. PubMed ID: 25843712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer.
    Gong K; Guo G; Panchani N; Bender ME; Gerber DE; Minna JD; Fattah F; Gao B; Peyton M; Kernstine K; Mukherjee B; Burma S; Chiang CM; Zhang S; Amod Sathe A; Xing C; Dao KH; Zhao D; Akbay EA; Habib AA
    Nat Cancer; 2020 Apr; 1(4):394-409. PubMed ID: 33269343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
    Meng S; Wang G; Lu Y; Fan Z
    Lung Cancer; 2018 Jul; 121():82-90. PubMed ID: 29858032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer.
    Zhang T; Zheng C; Hou K; Wang J; Zhang Y; Fan Y; Zhao H; Qu X; Liu Y; Kang J; Che X; Hu X
    Cell Biol Int; 2019 Feb; 43(2):98-107. PubMed ID: 29972257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p.
    Ma G; Zhu J; Liu F; Yang Y
    DNA Cell Biol; 2019 Feb; 38(2):176-183. PubMed ID: 30601026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of miR-1290 contributes to cell proliferation and invasion of non small cell lung cancer by targeting interferon regulatory factor 2.
    Jin JJ; Liu YH; Si JM; Ni R; Wang J
    Int J Biochem Cell Biol; 2018 Feb; 95():113-120. PubMed ID: 29275213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual effects of a CpG-DNAzyme targeting mutant EGFR transcripts in lung cancer cells: TLR9 activation and EGFR downregulation.
    Jang D; Baek YM; Park H; Hwang YE; Kim DE
    BMB Rep; 2018 Jan; 51(1):27-32. PubMed ID: 28893372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer.
    Zhao J; Guerrero A; Kelnar K; Peltier HJ; Bader AG
    Lung Cancer; 2017 Jun; 108():96-102. PubMed ID: 28625657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
    Zhou JY; Chen X; Zhao J; Bao Z; Chen X; Zhang P; Liu ZF; Zhou JY
    Cancer Lett; 2014 Sep; 351(2):265-71. PubMed ID: 24983493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Yang Z; Zhang SL; Hu X; Tam KY
    Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer.
    Sun W; Yuan X; Tian Y; Wu H; Xu H; Hu G; Wu K
    J Hematol Oncol; 2015 Jul; 8():95. PubMed ID: 26227959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.